Thomas Garner - Dec 9, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, Chief Commercial Officer
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Dec 9, 2024
Transactions value $
$0
Form type
4
Date filed
12/10/2024, 06:33 PM
Previous filing
Feb 12, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +236K $0.00 236K Dec 9, 2024 Common Stock 236K $18.76 Direct F1
transaction ACAD Restricted Stock Units Award $0 +45.4K $0.00 45.4K Dec 9, 2024 Common Stock 45.4K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option granted under the 2024 Equity Incentive Plan (the "Plan") will vest and become exercisable on December 9, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit granted under the Plan represents a contingent right to receive one share of the Issuer's common stock.
F3 50% of the restricted stock units vest on December 9, 2026 and 25% vest on each of December 9, 2027 and December 9, 2028.